As the Ford government faced one of the worst public health crises in Ontario's history, it convened more than 100 experts from policing, health, and lived experience to find solutions. Three years on...

KRASG12D is the predominant oncogenic driver in pancreatic ductal adenocarcinoma (PDAC). While most investigational KRAS-G12D inhibitors are oral small molecules limited by gastrointestinal toxicities and suboptimal tumor exposure, HRS-4642 is a new, high‑affinity, noncovalent KRAS-G12D inhibitor. Formulated as a liposomal nanoparticle for intravenous administration, it is designed to enhance tumor accumulation and prolong the duration of target inhibition. This phase 1b/2 study evaluated HRS-4642 in combination with nab-paclitaxel and gemcitabine (AG) in patients with advanced KRASG12D-mutant PDAC. As of 5 December 2025, 68 patients were screened and 31 (1 previously treated patient and 30 treatment-naive patients) were enrolled and treated. In the phase 1b portion, no dose-limiting toxicities were observed, and the starting dose (500 mg on day 1 and 1,200 mg on day 8, every 3 weeks) was selected as the recommended phase 2 dose. In the phase 2 portion, with a median follow-up of 12.3

Cancel culture has been linked, in recent times in Western democracies, to the suppression of freedom of expression in both academic and non-academic settings. I offer critical realism as a resourc...

Last December, former Senator Ben Sasse announced he had stage 4 pancreatic cancer. His doctors gave him three to four months to live. In January, he joined a clinical trial of daraxonrasib, Revolutio

Head and neck squamous cell carcinoma (HNSCC) represents a significant public health challenge. Its treatment is characterized by high anatomical complexity and a critical need for functional preservation of speech, swallowing, and respiration. While multimodality care, including surgery, radiotherapy, and systemic therapy, has substantially improved patient survival, there are still high rates of life-altering toxicities and low response rates to immunotherapy. Current clinical decision-making largely relies on “digital snapshots”—static representations derived from population-based statistics and time point–specific imaging—which usually fail to account for the rapid anatomical and biological change during the course of treatment. Digital twins hold great promise in accelerating scientific breakthroughs and transforming oncology treatment and precision medicine through the creation of high-fidelity virtual patient representations that integrate real-time biological, anatomical, and clinical data. In this viewpoint, we propose 3 interconnected digital twins to establish a conceptual framework for the HNSCC digital twin. These digital twins include the anatomical twin, using virtual surgical planning and augmented reality for geometric precision; the dosimetric twin, using daily imaging and synthetic computed tomography generation for automated adaptive radiotherapy; and the biological twin, integrating deep phenotyping, radiomics, and mechanistic omics to simulate individualized therapeutic trajectories. Beyond acute care, we explore the clinical utility of digital twins in navigating the “de-escalation dilemma” for human papillomavirus–associated disease and improving survivorship through digital phenotyping. With the advent of longitudinal data from medical-grade Internet-of-Things sensors and circulating tumor DNA kinetics, digital twins can serve as active sentinels, detecting functional decline or subclinical events months before clinical manifestation. Furthermore, the implementation of synthetic control arms via virtual populations offers an avenue to accelerate clinical trials and address ethical issues in rare molecular subtypes. Despite this potential, substantial barriers to implementation remain, including profound anatomical instability during treatment, the “black box” nature of deep learning algorithms, and the challenges of multiscale data integration. We provide a technical roadmap for the development of “morphing” digital twins—dynamic systems capable of continuous geometric and biological auditing. By bridging the gap between the macroscopic world of radiation physics and the microscopic world of cellular evolution, digital twins may help shift the management of HNSCC from population-based statistical probability toward more individualized, biologically informed decision-making, with the goal of optimizing HNSCC management while preserving essential patient functions.

Head and neck squamous cell carcinoma (HNSCC) represents a significant public health challenge. Its treatment is characterized by high anatomical complexity and a critical need for functional preservation of speech, swallowing, and respiration. While multimodality care, including surgery, radiotherapy, and systemic therapy, has substantially improved patient survival, there are still high rates of life-altering toxicities and low response rates to immunotherapy. Current clinical decision-making largely relies on “digital snapshots”—static representations derived from population-based statistics and time point–specific imaging—which usually fail to account for the rapid anatomical and biological change during the course of treatment. Digital twins hold great promise in accelerating scientific breakthroughs and transforming oncology treatment and precision medicine through the creation of high-fidelity virtual patient representations that integrate real-time biological, anatomical, and clinical data. In this viewpoint, we propose 3 interconnected digital twins to establish a conceptual framework for the HNSCC digital twin. These digital twins include the anatomical twin, using virtual surgical planning and augmented reality for geometric precision; the dosimetric twin, using daily imaging and synthetic computed tomography generation for automated adaptive radiotherapy; and the biological twin, integrating deep phenotyping, radiomics, and mechanistic omics to simulate individualized therapeutic trajectories. Beyond acute care, we explore the clinical utility of digital twins in navigating the “de-escalation dilemma” for human papillomavirus–associated disease and improving survivorship through digital phenotyping. With the advent of longitudinal data from medical-grade Internet-of-Things sensors and circulating tumor DNA kinetics, digital twins can serve as active sentinels, detecting functional decline or subclinical events months before clinical manifestation. Furthermore, the implementation of synthetic control arms via virtual populations offers an avenue to accelerate clinical trials and address ethical issues in rare molecular subtypes. Despite this potential, substantial barriers to implementation remain, including profound anatomical instability during treatment, the “black box” nature of deep learning algorithms, and the challenges of multiscale data integration. We provide a technical roadmap for the development of “morphing” digital twins—dynamic systems capable of continuous geometric and biological auditing. By bridging the gap between the macroscopic world of radiation physics and the microscopic world of cellular evolution, digital twins may help shift the management of HNSCC from population-based statistical probability toward more individualized, biologically informed decision-making, with the goal of optimizing HNSCC management while preserving essential patient functions.

Actinium Pharmaceuticals (ATNM) announced an ASH 2026 abstract evaluating long-term safety of Actimab-A plus CLAG-M chemotherapy in relapsed or refractory acute myeloid leukemia.The Phase 1 follow-up examines blood count recovery and potential delayed kidney and liver toxicities among patients who survived at least three months after treatment. Previously presented ASH 2022 data reported estimated one-year and two-year overall survival of 59% and 32% in patients previously treated with venetoclax, and 51% and 19% in patients with TP53-mutated disease. Actinium said the findings support further evaluation of Actimab-A as a potential treatment backbone across mutations in CD33-positive AML. The poster is scheduled for December 13, 2026.

A briefing to state bureaucrats shows the new NDIS needs assessment tool will be almost identical to the dangerously flawed aged-care tool criticised by the Commonwealth ombudsman this week.

Orthohantaviruses represent a persistent global health threat, being responsible for life-threatening diseases such as Hemorrhagic Fever with Renal Syndrome (HFRS) and Hantavirus Cardiopulmonary Syndrome (HCPS). Despite high case fatality rates and recent outbreaks, there are currently no universally licensed antivirals or vaccines. Clinical management remains heavily reliant on supportive care and repurposed drugs, which often exhibit limited efficacy and dose-limiting toxicities. This review...